Optas LLC Raises Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Optas LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 22.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 795 shares of the medical equipment provider’s stock after purchasing an additional 144 shares during the period. Optas LLC’s holdings in Intuitive Surgical were worth $415,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ISRG. State Street Corp grew its position in shares of Intuitive Surgical by 1.4% during the 3rd quarter. State Street Corp now owns 15,050,121 shares of the medical equipment provider’s stock worth $7,393,673,000 after buying an additional 210,363 shares in the last quarter. FMR LLC grew its holdings in Intuitive Surgical by 8.3% during the 3rd quarter. FMR LLC now owns 10,971,085 shares of the medical equipment provider’s stock worth $5,389,765,000 after acquiring an additional 838,793 shares in the last quarter. Geode Capital Management LLC increased its position in Intuitive Surgical by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 7,512,925 shares of the medical equipment provider’s stock valued at $3,677,194,000 after purchasing an additional 143,440 shares during the period. Fisher Asset Management LLC raised its holdings in shares of Intuitive Surgical by 1.8% in the 3rd quarter. Fisher Asset Management LLC now owns 4,782,381 shares of the medical equipment provider’s stock valued at $2,349,441,000 after purchasing an additional 86,208 shares in the last quarter. Finally, Baillie Gifford & Co. lifted its position in shares of Intuitive Surgical by 0.6% in the 3rd quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock worth $1,890,676,000 after purchasing an additional 24,183 shares during the period. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

NASDAQ:ISRG opened at $578.55 on Tuesday. The company’s fifty day moving average price is $550.40 and its 200-day moving average price is $510.02. Intuitive Surgical, Inc. has a 1-year low of $364.17 and a 1-year high of $616.00. The firm has a market capitalization of $206.07 billion, a P/E ratio of 90.26, a PEG ratio of 5.51 and a beta of 1.39.

Insiders Place Their Bets

In related news, Director Amal M. Johnson sold 4,635 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $566.60, for a total transaction of $2,626,191.00. Following the sale, the director now directly owns 12,275 shares of the company’s stock, valued at $6,955,015. This trade represents a 27.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Jamie Samath sold 108 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $542.06, for a total value of $58,542.48. Following the completion of the transaction, the chief financial officer now directly owns 8,757 shares of the company’s stock, valued at $4,746,819.42. The trade was a 1.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 28,843 shares of company stock valued at $15,357,560. Company insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the topic of several research reports. Morgan Stanley raised shares of Intuitive Surgical from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $522.00 to $650.00 in a report on Monday, December 2nd. Mizuho boosted their price target on Intuitive Surgical from $440.00 to $500.00 in a research report on Thursday, October 17th. Citigroup raised their price objective on Intuitive Surgical from $640.00 to $711.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Barclays boosted their target price on shares of Intuitive Surgical from $610.00 to $674.00 in a report on Monday, January 27th. Finally, Leerink Partners raised their price target on shares of Intuitive Surgical from $490.00 to $548.00 in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $613.10.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.